Article Text
Abstract
Introduction/Background Vulvar cancer accounts for 5% of gynecological tumors. However, the presence of comorbidities and the impact of surgical complications are a challenge for both, patients, and medical team. Furthermore, delays in adjuvant treatment have been demonstrated as detrimental prognostic factor. Our objective was to assess the complication rate in our series and determine which factors could have an impact on its appearance.
Methodology Retrospective analysis of all consecutive patients treated for early stages (FIGO I-II) squamous cell carcinoma of the vulva with primary surgery, in a single institution (2010 to 2023). All clinical factors have been compared between patients who experienced complications (group 1) and those who did not (group 2).
Results A total of 76 patients were divided in two groups: absence of complications 44/76 (57,9%) vs who experienced any complication 32/76 (42,1%) being the main complication the dehiscence of suture (28.9%; 22/76). No significant differences were observed between groups in: BMI, ASA classification, smoke habit, tumor localization, clinical tumor size, infiltrations of urethra or anus, uni or multifocal, hemi vulvectomy or total vulvectomy. Significant differences were observed in mean age (70.1 years vs 76.6 years; p=0.014) and mean Charlson index (5.3 vs 6.3; p=0,049), for no-complications group vs complications group respectively. Only 4% (2/49) of patients experienced a delay in the onset of adjuvant therapy, corresponding all of them to complication group. Charlson Index was the only independent factor for surgical complication OR 1.53 95%CI (1.104–2.121) at multivariate analysis.
Conclusion Surgical complications secondary to vulvar cancer surgery affect nearly half of the patients, whit potential impact on hospital staging and delaying adjuvant treatment. Advanced age and Charlson Index may be predictors of complications even independently of all other potential factors. However, more studies are needed that explore adapted treatment or intensive prehabilitation in these especially frail patients.
Disclosures No conflict of interest to disclaim.